Your browser doesn't support javascript.
loading
Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL.
Erdmann, Tabea; Klener, Pavel; Lynch, James T; Grau, Michael; Vocková, Petra; Molinsky, Jan; Tuskova, Diana; Hudson, Kevin; Polanska, Urszula M; Grondine, Michael; Mayo, Michele; Dai, Beiying; Pfeifer, Matthias; Erdmann, Kristian; Schwammbach, Daniela; Zapukhlyak, Myroslav; Staiger, Annette M; Ott, German; Berdel, Wolfgang E; Davies, Barry R; Cruzalegui, Francisco; Trneny, Marek; Lenz, Peter; Barry, Simon T; Lenz, Georg.
Afiliación
  • Erdmann T; Translational Oncology, University Hospital Münster, Münster, Germany.
  • Klener P; Cluster of Excellence EXC 1003, Cells in Motion, Münster, Germany.
  • Lynch JT; Fachbereich Chemie und Pharmazie, University of Münster, Münster, Germany.
  • Grau M; Institute of Pathological Physiology, First Faculty of Medicine, Charles University Prague, Prague, Czech Republic.
  • Vocková P; First Medical Department, Department of Hematology, Charles University General Hospital Prague, Prague, Czech Republic.
  • Molinsky J; Innovative Medicines and Early Development (IMED) Oncology AstraZeneca, Li Ka Shing Centre, Cambridge, United Kingdom.
  • Tuskova D; Translational Oncology, University Hospital Münster, Münster, Germany.
  • Hudson K; Cluster of Excellence EXC 1003, Cells in Motion, Münster, Germany.
  • Polanska UM; Institute of Pathological Physiology, First Faculty of Medicine, Charles University Prague, Prague, Czech Republic.
  • Grondine M; First Medical Department, Department of Hematology, Charles University General Hospital Prague, Prague, Czech Republic.
  • Mayo M; Institute of Pathological Physiology, First Faculty of Medicine, Charles University Prague, Prague, Czech Republic.
  • Dai B; First Medical Department, Department of Hematology, Charles University General Hospital Prague, Prague, Czech Republic.
  • Pfeifer M; Institute of Pathological Physiology, First Faculty of Medicine, Charles University Prague, Prague, Czech Republic.
  • Erdmann K; First Medical Department, Department of Hematology, Charles University General Hospital Prague, Prague, Czech Republic.
  • Schwammbach D; Innovative Medicines and Early Development (IMED) Oncology AstraZeneca, Li Ka Shing Centre, Cambridge, United Kingdom.
  • Zapukhlyak M; Innovative Medicines and Early Development (IMED) Oncology AstraZeneca, Li Ka Shing Centre, Cambridge, United Kingdom.
  • Staiger AM; IMED Oncology AstraZeneca, Gatehouse Park, Boston, MA.
  • Ott G; IMED Oncology AstraZeneca, Gatehouse Park, Boston, MA.
  • Berdel WE; Translational Oncology, University Hospital Münster, Münster, Germany.
  • Davies BR; Cluster of Excellence EXC 1003, Cells in Motion, Münster, Germany.
  • Cruzalegui F; Division of Cancer, Department of Surgery & Cancer, Imperial College, London, United Kingdom.
  • Trneny M; Translational Oncology, University Hospital Münster, Münster, Germany.
  • Lenz P; Cluster of Excellence EXC 1003, Cells in Motion, Münster, Germany.
  • Barry ST; Translational Oncology, University Hospital Münster, Münster, Germany.
  • Lenz G; Cluster of Excellence EXC 1003, Cells in Motion, Münster, Germany.
Blood ; 130(3): 310-322, 2017 07 20.
Article en En | MEDLINE | ID: mdl-28202458
Asunto(s)
Antineoplásicos/farmacología; Regulación Neoplásica de la Expresión Génica; Linfoma de Células B Grandes Difuso/tratamiento farmacológico; Oxadiazoles/farmacología; Piperidinas/farmacología; Inhibidores de Proteínas Quinasas/farmacología; Pirazoles/farmacología; Pirimidinas/farmacología; Pirroles/farmacología; Adenina/análogos & derivados; Agammaglobulinemia Tirosina Quinasa; Animales; Apoptosis/efectos de los fármacos; Combinación de Medicamentos; Ensayos de Selección de Medicamentos Antitumorales; Sinergismo Farmacológico; Humanos; Linfoma de Células B Grandes Difuso/clasificación; Linfoma de Células B Grandes Difuso/genética; Linfoma de Células B Grandes Difuso/patología; Ratones; FN-kappa B/antagonistas & inhibidores; FN-kappa B/genética; FN-kappa B/metabolismo; Especificidad de Órganos; Fosfohidrolasa PTEN/deficiencia; Fosfohidrolasa PTEN/genética; Fosfatidilinositol 3-Quinasas/genética; Fosfatidilinositol 3-Quinasas/metabolismo; Inhibidores de las Quinasa Fosfoinosítidos-3; Proteínas Tirosina Quinasas/antagonistas & inhibidores; Proteínas Tirosina Quinasas/genética; Proteínas Tirosina Quinasas/metabolismo; Proteínas Proto-Oncogénicas c-akt/antagonistas & inhibidores; Proteínas Proto-Oncogénicas c-akt/genética; Proteínas Proto-Oncogénicas c-akt/metabolismo; Proteínas Proto-Oncogénicas c-myc/antagonistas & inhibidores; Proteínas Proto-Oncogénicas c-myc/genética; Proteínas Proto-Oncogénicas c-myc/metabolismo; Transducción de Señal; Ensayos Antitumor por Modelo de Xenoinjerto
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Oxadiazoles / Piperidinas / Pirazoles / Pirimidinas / Pirroles / Regulación Neoplásica de la Expresión Génica / Linfoma de Células B Grandes Difuso / Inhibidores de Proteínas Quinasas / Antineoplásicos Tipo de estudio: Diagnostic_studies / Prognostic_studies Idioma: En Revista: Blood Año: 2017 Tipo del documento: Article País de afiliación: Alemania
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Oxadiazoles / Piperidinas / Pirazoles / Pirimidinas / Pirroles / Regulación Neoplásica de la Expresión Génica / Linfoma de Células B Grandes Difuso / Inhibidores de Proteínas Quinasas / Antineoplásicos Tipo de estudio: Diagnostic_studies / Prognostic_studies Idioma: En Revista: Blood Año: 2017 Tipo del documento: Article País de afiliación: Alemania